Omega-3 Supplementation and Immunotherapy in Gastric Cancer: A Phase II Trial

Participants assigned to the experimental group will receive Omega-3 fatty acids supplementation as part of their treatment regimen. The Omega-3 supplementation will consist of high-quality fish oil capsules, providing a daily dose of \[specific dosage, e.g., 2000 mg of EPA and DHA combined\], taken orally. This supplementation will commence concurrently with the initiation of neoadjuvant immunotherapy and will continue throughout the treatment period.

"Participants in both the experimental and control groups will receive neoadjuvant immunotherapy designed to stimulate the body's immune response against locally advanced gastric and gastroesophageal junction adenocarcinomas. The specific regimen will involve administration of \[specific immunotherapeutic agents, e.g., pembrolizumab, nivolumab, etc.\] in accordance with established clinical protocols.~The neoadjuvant immunotherapy will be administered through intravenous infusion, typically starting \[specify timeline, e.g., 4-6 weeks\] prior to surgical resection of the tumor. Treatment cycles will be scheduled every \[specify interval, e.g., 2 or 3 weeks\], depending on the specific agent used and participant response."